GW1929

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

GW1929 是一种有效的 PPAR-γ 激动剂（人 PPAR-γ 的 pKi：8.84；人和鼠 PPAR-γ 的 pEC50 分别为 8.56 和 8.27）。

GW1929 is a potent PPAR-γ agonist (pKi: 8.84 for human PPAR-γ; pEC50s of 8.56 and 8.27 for human and murine PPAR-γ).GW1929 is a potent PPAR-γ activator, with pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, and pKis of 8.84, < 5.5, and < 6.5 for human PPAR-γ, PPAR-α, and PPAR-δ, respectively. GW1929 (10 μM) inhibits TBBPA-induced caspase-3 increase and TBBPA-stimulated LDH release in neocortical cell cultures [2].GW1929 (0.5, 1, 5 mg/kg, p.o.) highly decreases nonfasted plasma glucose levels in Zucker diabetic fatty (ZDF) rats after treatment for 14 days and possesses antilipolytic efficacy. In ZDF rats, GW1929 (1, 5 mg/kg, p.o.) increases glucose-stimulated insulin secretion of β-cell.

——

——

——

Metabolic Enzyme/Protease

PPAR

PPARγ

Cardiovascular system

Type 2 diabetes mellitus

196808-24-9

495.57

C30H29N3O4

>98% (HPLC)

DMSO:33 mg/mL (66.59 mM)

CN(CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(O)=O)cc1)c1ccccn1

——

(-20℃)

With Ice Pack

≥ 2 years